Area of research
Oncology · Computational Theory and Mathematics
Research interest
Research interests include PARP inhibition in cancer therapy, Computational Drug Discovery Methods, Cell Image Analysis Techniques, and Bioinformatics and Genomic Networks.
Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma.
PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation.
Author Correction: PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation.
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models.
ADP-ribosyltransferases, an update on function and nomenclature.
Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop.
Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response.
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven adaptive resistance
ADP‐ribosyltransferases, an update on function and nomenclature
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.
Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule.
Selective pharmaceutical inhibition of PARP14 mitigates allergen-induced IgE and mucus overproduction in a mouse model of pulmonary allergic response
Multiplexed and reproducible high content screening of live and fixed cells using the Dye Drop method
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement.
Receptor-based mechanism of relative sensing and cell memory in mammalian signaling networks.
Maximum Entropy Framework for Predictive Inference of Cell Population Heterogeneity and Responses in Signaling Networks.
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.
Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
Tensor clustering with algebraic constraints gives interpretable groups of crosstalk mechanisms in breast cancer.
The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations
Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
L1000CDS2: LINCS L1000 characteristic direction signatures search engine
LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures
Discovering causal pathways linking genomic events to transcriptional states using Tied Diffusion Through Interacting Events (TieDIE)
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Discovery of Potent and Selective Covalent Inhibitors of JNK
Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics